Research

Hormonal

Weekly subcutaneous administration of IBI362, a GLP-1 and glucagon receptor dual agonist, produces significant body weight loss and improves metabolic parameters in Chinese adults with overweight or obesity.

IBI362 is a once-weekly injection that helps overweight and obese Chinese adults lose weight and improve metabolic health. It works by targeting two hormones (GLP-1 and glucagon) to reduce appetite and increase energy expenditure. In this study, participants lost between 4.8% and 6.4% of their body weight over 12 weeks, with side effects like nausea being mostly mild. This suggests it is a viable option for those seeking pharmacological weight loss support.

ModerateSupportsMEDIUM confidence
IBI362 was well tolerated and showed a body weight-lowering effect in Chinese adults with overweight or obesity.
Linong Ji et al. · EClinicalMedicine · 2021

Why this rating

Phase 1b study with small sample size (n=36) and short duration (12 weeks), but randomized and placebo-controlled.

Source

IBI362 (LY3305677), a weekly-dose GLP-1 and glucagon receptor dual agonist, in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple ascending dose phase 1b study

Linong Ji et al. · EClinicalMedicine · 2021

DOI 10.1016/j.eclinm.2021.101088

rct · n=36Cited 55×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →